NH Theraguix

NH Theraguix is a clinical pharmaceutical company specializing in the development of nanomedicine for oncology imaging and radiotherapy. Founded in December 2015, the company emerged from over a decade of research collaboration between the University of Lyon and international academic partners. NH Theraguix focuses on transferring a new family of nanoparticles called AGuIX to clinical applications. The company's innovative technology is protected by eight patents and has demonstrated proof of concept for radiation dose amplification in six different animal tumor models. NH Theraguix has successfully developed ultra-small nanoparticles for cancer treatment, which were the first hybrid theranostic nanoparticles to be intravenously injected in humans after completing regulatory toxicology studies.

Through federal grant sub-awards, NH Theraguix has been collaborating with the Dana-Farber Cancer Institute (DFCI) on preclinical testing of nanoparticles for cancer treatment. The company synthesizes nanoparticles, performs initial physical characterization, and conducts quality assurance before shipping dry nanoparticles to DFCI for evaluation in biological systems with radiation. NH Theraguix contributes to experimental design, troubleshooting, data analysis, and results communication. The collaboration has resulted in seven published papers and a shared patent application for Bi-AGuIX, a new nanoparticle formulation including bismuth that has shown increased therapeutic efficacy in non-small cell lung cancer mouse models. NH Theraguix has also conducted clinical trials, including a Phase I trial (NANORAD) for treating brain metastases with MR-guided radiation therapy and another Phase I trial (NANOCOL) for advanced cervical cancer treatment. The company's work demonstrates significant potential for enhancing radiation therapy outcomes in cancer patients through the use of innovative nanoparticle technology.